Two Strains and Drug Adherence: An HIV Model in the Paradigm of Community Transmission

Overview

Journal Nonlinear Dyn

Date 2022 Mar 21

PMID 35310019

Authors

Ashish Poonia

Siddhartha P Chakrabarty

Affiliations

Soon will be listed here.

Abstract

A two-strain model, comprising of drug-sensitive and drug-resistant strains, is proposed for the dynamics of Human Immunodeficiency Virus (HIV) spread in a community. A treatment model is introduced by taking drug adherence into account. The treatment-free model is analyzed for the effect of treatment availability and drug adherence on disease dynamics. The analysis revealed that for the treatment-free model, at least one strain faces competitive exclusion, and co-existence of both strains is not possible. On the contrary, both strains may co-exist in presence of treatment. The analysis carried out was both local, as well as global. A comprehensive bifurcation analysis showed periodic behaviour and all solutions approached a stable limit cycle for a wide range of parametric values. Overall, we concluded that the treatment availability and drug adherence play a significant role in determining the dynamics of HIV spread. Numerical simulations are performed to validate the analytical results using MATLAB.

References

Harrigan P, Hogg R, Dong W, Yip B, Wynhoven B, Woodward J . Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005; 191(3):339-47. DOI: 10.1086/427192. View

Kozal M . Drug-resistant human immunodefiency virus. Clin Microbiol Infect. 2009; 15 Suppl 1:69-73. DOI: 10.1111/j.1469-0691.2008.02687.x. View

Castillo-Chavez C, Song B . Dynamical models of tuberculosis and their applications. Math Biosci Eng. 2010; 1(2):361-404. DOI: 10.3934/mbe.2004.1.361. View

Kumar V, Encinosa W . Effects of HIV Medication Complexity and Depression on Adherence to HIV Medication. Patient. 2012; 3(1):59-69. DOI: 10.2165/11531090-000000000-00000. View

Little S, Holte S, Routy J, Daar E, Markowitz M, Collier A . Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002; 347(6):385-94. DOI: 10.1056/NEJMoa013552. View

Trebelcock W, Lama J, Duerr A, Sanchez H, Cabello R, Gilada T . HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru. J Int AIDS Soc. 2019; 22(11):e25411. PMC: 6880186. DOI: 10.1002/jia2.25411. View

Nachega J, Marconi V, van Zyl G, Gardner E, Preiser W, Hong S . HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011; 11(2):167-74. PMC: 5072419. DOI: 10.2174/187152611795589663. View

Munita J, Arias C . Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016; 4(2). PMC: 4888801. DOI: 10.1128/microbiolspec.VMBF-0016-2015. View

Dworkin M, Chakraborty A, Zychowski D, Donenberg G, Novak R, Garofalo R . Self-efficacy and ability to read as factors associated with antiretroviral therapy adherence in an HIV-infected population. Int J STD AIDS. 2018; 29(12):1154-1164. DOI: 10.1177/0956462418776073. View

10.

Paterson D, Swindells S, Mohr J, BRESTER M, Vergis E, Squier C . Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133(1):21-30. DOI: 10.7326/0003-4819-133-1-200007040-00004. View

11.

Anderson R, Medley G, May R, Johnson A . A preliminary study of the transmission dynamics of the human immunodeficiency virus (HIV), the causative agent of AIDS. IMA J Math Appl Med Biol. 1986; 3(4):229-63. DOI: 10.1093/imammb/3.4.229. View

12.

Jewell B, Mudimu E, Stover J, Ten Brink D, Phillips A, Smith J . Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. Lancet HIV. 2020; 7(9):e629-e640. PMC: 7482434. DOI: 10.1016/S2352-3018(20)30211-3. View

13.

Ballivian J, Alcaide M, Cecchini D, Jones D, Abbamonte J, Cassetti I . Impact of COVID-19-Related Stress and Lockdown on Mental Health Among People Living With HIV in Argentina. J Acquir Immune Defic Syndr. 2020; 85(4):475-482. DOI: 10.1097/QAI.0000000000002493. View

14.

Achappa B, Madi D, Bhaskaran U, Ramapuram J, Rao S, Mahalingam S . Adherence to Antiretroviral Therapy Among People Living with HIV. N Am J Med Sci. 2013; 5(3):220-3. PMC: 3632027. DOI: 10.4103/1947-2714.109196. View

15.

Wood E, Hogg R, Yip B, Harrigan P, OShaughnessy M, Montaner J . Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?. AIDS. 2003; 17(5):711-20. DOI: 10.1097/00002030-200303280-00009. View

16.

Nakagawa F, May M, Phillips A . Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2012; 26(1):17-25. DOI: 10.1097/QCO.0b013e32835ba6b1. View

17.

Zhang T, Wang J, Li Y, Jiang Z, Han X . Dynamics analysis of a delayed virus model with two different transmission methods and treatments. Adv Differ Equ. 2020; 2020(1):1. PMC: 7100214. DOI: 10.1186/s13662-019-2438-0. View

18.

Mohammadi-Moein H, Maracy M, Tayeri K . Life expectancy after HIV diagnosis based on data from the counseling center for behavioral diseases. J Res Med Sci. 2014; 18(12):1040-5. PMC: 3908523. View

19.

Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R . Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002; 46(2):93-108. DOI: 10.1016/s0738-3991(01)00219-1. View

20.

Vernazza P, Eron J, Fiscus S, Cohen M . Sexual transmission of HIV: infectiousness and prevention. AIDS. 1999; 13(2):155-66. DOI: 10.1097/00002030-199902040-00003. View